Ibrutinib is an anticancer drug targeting b-cell malignancies. it is an orally-administered, selective and covalent inhibitor of the enzyme bruton s tyrosine kinase (btk).ibrutinib was fda-approved as a treatment for mantle cell lymphoma and chronic lymphocytic leukemia.
Voir plus de détails